Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
42.69
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 18th, 8:20 AM EDT
Detailed Quote
Previous Close
42.69
Open
-
Bid
38.25
Ask
49.75
Day's Range
N/A - N/A
52 Week Range
29.16 - 43.62
Volume
3
Market Cap
2.27B
PE Ratio (TTM)
37.12
EPS (TTM)
1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,037,172
Chart
About Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD). The company leverages its proprietary drug formulation technologies to create specialized medications that enhance patient outcomes. With a commitment to addressing unmet medical needs, Supernus actively engages in research and development, aiming to expand its product offerings and provide effective treatment solutions for patients suffering from these challenging conditions. Read More
Supernus Pharmaceuticals (SUPN) offers strong growth, solid profitability, and fair valuations, making it an ideal pick for Affordable Growth investors.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Zoetis (NYSE:ZTS).
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The company’s full-year revenue guidance of $685 million at the midpoint came in 5.3% above analysts’ estimates. Its non-GAAP profit of $0.91 per share was 94.8% above analysts’ consensus estimates.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its peers.
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
jumped 14.4% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year revenue forecast. The pharmaceutical company reported revenues of $165.5 million, which surpassed analysts' projections, while its earnings per share of $0.40 also beat consensus estimates. Investors reacted positively to the growth in key products, as net sales for Qelbree and GOCOVRI increased by 31% and 16% respectively, compared to the prior year. Bolstering investor confidence, Supernus lifted its full-year revenue guidance, pointing to a strong first-half performance. The company also completed the acquisition of Sage Therapeutics and launched a new device for Parkinson's disease, which further supported the positive sentiment.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The company’s full-year revenue guidance of $685 million at the midpoint came in 7.6% above analysts’ estimates. Its GAAP profit of $0.40 per share was significantly above analysts’ consensus estimates.
ROCKVILLE, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2025 and associated Company developments.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be reporting results this Tuesday afternoon. Here’s what investors should know.
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its price target to $42 from $36. The upgrade followed positive developments in the company's planned acquisition of Sage Therapeutics. Supernus announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the deal had expired. The expiration of this period, a requirement for major mergers and acquisitions in the U.S., removed a key regulatory hurdle, allowing the transaction to proceed. The tender offer for Sage shares was set to expire on July 30, 2025, after which Supernus planned to complete the merger. This acquisition was expected to enhance Supernus's product portfolio with Sage's innovative treatments, a move that likely bolstered analyst confidence.
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is an undervalued stock with strong profitability, no debt, and steady growth—making it a potential pick for value investors.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
